RxDoctor Payments Data

Arvin Saluta, MD

Internal Medicine · San Diego, CANPI 1942213715

Payments from drug & device makers

$5,215in general payments, 2019–2025

Across 186 payments — averaging $28.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$3K
  • Gilead$1K
  • Johnson & Johnson$363
  • Janssen Products, LP$250
  • Mylan Specialty L.p.$46
  • Mylan Pharmaceuticals Inc.$41
  • plus $20 from 1 others

What the payments were for

  • Travel & lodging$331%
  • Food & beverage$5,11998%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,215 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$32,441
Medicare patients
91
Services billed
590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SerostimSomatropin15$316,728
TivicayDolutegravir Sodium93$246,533
DovatoDolutegravir Sodium/Lamivudine76$229,798
DescovyEmtricitabine/Tenofov Alafenam73$208,720
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf42$198,622
TriumeqAbacavir/Dolutegravir/Lamivudi41$197,024
BiktarvyBictegrav/Emtricit/Tenofov Ala45$185,525
PrezcobixDarunavir/Cobicistat60$170,166
GenvoyaElviteg/Cob/Emtri/Tenof Alafen38$167,446
OdefseyEmtricitab/Rilpiviri/Tenof Ala38$159,200
JardianceEmpagliflozin60$74,174
IsentressRaltegravir Potassium25$49,418
EliquisApixaban32$38,379
CompleraEmtricita/Rilpivirine/Tenof Df11$36,159
OzempicSemaglutide30$28,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Dovato, Triumeq$3,272$673,355210 claims
GileadDescovy, Biktarvy, Genvoya$1,225$561,692156 claims
Johnson & JohnsonPrezcobix, Complera, Xarelto$363$227,229102 claims
Janssen Products, LPSymtuza$250$198,62242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →